When the tumors grew 12 13 mm in diameter, the mice were assigned to the control (n = 5) and sorafenib-treated (n = 5) groups.
The A498 xenograft was established in nude mice, and the mice were assigned to the control (n = 5) and treatment (n = 5) groups.
In the second set of in vivo experiments, the mice were assigned to 3 groups (control, paclitaxel alone, or combined paclitaxel and DHMEQ), each consisting of 10 animals.
Tumors were implanted in mice (5 × 10 Hcells cells), and 3 weeks later, the mice were assigned to one of the three groups; Os (500 μg), Os (1 mg) or DMSO (solvent control) two times a week during 3 weeks.
On day 35, the mice were assigned to seven different treatment groups (five mice per group) as follows: Group 1: 0.9% NaCl i.v. injection alone (200 μl injection−1) for this control group on days 34, 37, 41, 44, and 48.
When the volume of the transplantation tumor reached 100 mm, the mice were assigned randomly into four treatment groups: control (n = 5), cilostazol alone (n = 5), CDDP alone (n = 5), and cilostazol combined with CDDP (n = 5).
Depending on the needle gauge, each CLP mouse was assigned to either (1) CLP-Only or (2) CLP-ODam.
Each mouse was assigned either the left or right lever to the active lever, and the side of the active lever was counterbalanced between mice within each genotype.
During the testing, mice were assigned into different groups (n=8 for each group).
Before initiating the study, 20 mice were assigned to four groups.
The ob/ ob mice were assigned to three groups of eight and dosed orally daily at 8 am with 0.5%hydroxypropylmethylcellulose/0.1%Tween8080 vehicle control, a PPARδ agonist, GW610742 (30 mg/kg), and a PPARγ agonist, GW347845 (5 mg/kg).
